Polyrizon Ltd. announced the filing of a divisional European patent application for its Trap & Target (T&T) intranasal drug delivery platform, expanding its global intellectual property portfolio.
Key takeaways
The Company filed a divisional patent application with the European Patent Office for its Trap & Target (T&T) platform technology.
The T&T platform is designed to enhance drug effectiveness by increasing residence time and ensuring close contact with mucosal tissues.
This European filing aligns with a recently announced U.S. patent application covering both the C&C and T&T platform technologies.
The platform aims to improve bioavailability of active pharmaceutical ingredients (APIs) for local and systemic drug delivery.
Potential applications include delivery of corticosteroids, benzodiazepines, and naloxone for various medical conditions.